As homologs of adenosine triphosphate (ATP), TKIs competitively occupy the ATPs-binding site of PTKs and block PTK-mediated signaling pathways in cancer cells, thereby inhibiting their growth and proliferation. This evidence concerns the gene PTK2B and cancer.